GLP-1 Receptor Agonists
Mechanisms · Agents · Cardiovascular Outcome Trials · Safety
Multi-Organ Effects of GLP-1 Receptor Activation
Pancreas (Beta Cell)
  • Glucose-dependent insulin secretion ↑
  • Glucagon suppression (alpha cell)
  • Low hypoglycemia risk as monotherapy
Brain / Hypothalamus
  • Appetite suppression
  • Satiety signaling ↑
  • 10–15% body weight loss (high doses)
GI Tract
  • Gastric emptying slowed
  • Postprandial glucose excursion reduced
  • Nausea/vomiting (dose-dependent)
Heart & Vessels
  • Anti-inflammatory effects
  • Reduced atherosclerotic progression
  • MACE reduction in CVOTs
Cardiovascular Outcome Trials (CVOTs)
TrialAgentDosingCV ResultKey Finding
LEADERLiraglutideOnce daily Benefit 13% MACE reduction; cardiovascular mortality driven
SUSTAIN-6Semaglutide SCOnce weekly Benefit 26% MACE reduction; stroke benefit prominent
REWINDDulaglutideOnce weekly Benefit Benefit in primary and secondary prevention populations
PIONEER-6Semaglutide oralOnce daily Benefit 21% MACE reduction (not statistically significant alone)
ELIXALixisenatideOnce daily Neutral No benefit, no harm; exendin-based agent
EXSCELExenatide EROnce weekly Neutral No significant MACE reduction; exendin-based agent
MACE = major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke). Benefit seen with human GLP-1 analogs; neutral with exendin-based agents.
Agent Dosing Frequency
  • Twice daily: exenatide (Byetta)
  • Once daily injection: liraglutide, lixisenatide
  • Once daily oral: semaglutide (Rybelsus) — fasting, 30 min before food
  • Once weekly: semaglutide SC, dulaglutide, exenatide ER
  • Longer dosing interval improves adherence; once-weekly preferred
Adverse Effects and Contraindications
  • Nausea 20–40%: dose-dependent, improves with titration
  • Vomiting and diarrhea: less common, same mechanism
  • Pancreatitis: rare; discontinue if confirmed
  • Contraindicated: personal/family history of medullary thyroid carcinoma
  • Contraindicated: multiple endocrine neoplasia type 2
  • Avoid in gastroparesis; switch to insulin in pregnancy